CERUS CORP
No enriched coverage for $CERS in the last 7 days.
CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cers-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cerus Corporation Announces Second Quarter 2026 Financial Results Second Quarter 2026 Total Revenue of $63.3 million; Second Quarter 2026 Product Revenue of $57.4 million, +10% Y/Y Raising Lower End of 2026 Product Revenue Gu
CERUS CORP (CERS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001020214 0001020214 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2
CERUS CORP (CERS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001020214 0001020214 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05,
Recent CERS coverage spans financial news, corporate actions and earnings.
In the last 30 days, CERS insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($53K). The most active reporter was Jayaraman Vivek K, Chief Executive Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Guidance raise plus continued IFC volume growth supports a near-term positive re-rating, tempered by margin compression and lower cash.
Board/exec role transition is unlikely to change near-term fundamentals, but it can affect governance optics and cash compensation expectations.
New secured credit facilities refinance part of existing term debt and expand liquidity, with floating-rate costs and covenants that can affect near-term risk and funding flexibility.
Insider selling disclosed via Form 4; likely low fundamental signal given 10b5-1 pre-arrangement, but can affect near-term sentiment/flow.
Cerus Corporation reported strong Q1 2026 financial results, with significant revenue growth and narrowed losses, leading to a bullish outlook for the stock.
alphai scores every news story that mentions CERS with an AI model for sentiment and relevance, and aggregates insider trades from CERUS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cers-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cerus Corporation Announces Second Quarter 2026 Financial Results Second Quarter 2026 Total Revenue of $63.3 million; Second Quarter 2026 Product Revenue of $57.4 million, +10% Y/Y Raising Lower End of 2026 Product Revenue Gu
6 min readCERUS CORP (CERS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001020214 0001020214 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2
2 min readCERUS CORP (CERS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001020214 0001020214 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05,
4 min readJayaraman Vivek K (Chief Operating Officer) sold 16,667 shares of CERUS CORP (CERS) at $3.00 on 2026-05-29 under a Rule 10b5-1 trading plan.
1 min readCerus Corporation reported strong financial results for the first quarter of 2026, with total revenue increasing by 23% to $59.9 million and product revenue by 24% to $53.7 million. The company significantly narrowed its net loss to $1.6 million and saw increased demand for its INTERCEPT Fibrinogen Complex. Based on this performance, Cerus raised its full-year 2026 product revenue guidance to a range of $227 million to $231 million.
2 min readSumitomo Mitsui Trust Group Inc. reduced its stake in Cerus Corporation by 6.3% during the third quarter, selling 384,660 shares and holding 5,685,177 shares valued at $9.04 million. Despite this, other hedge funds like AQR Capital Management and Millennium Management increased their positions, with institutional investors and hedge funds collectively owning 78.37% of the stock. Analyst ratings are mixed, resulting in a consensus "Hold" rating and a $4.00 price target, while Cerus's stock saw a 5.1% drop to $2.60.
3 min readCerus (CERS) delivered earnings and revenue surprises of 20% and 2.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min read
